Retatrutide
Also known as: GLP-1/GIP/glucagon triple agonist, LY3437943
Pricing — All Vial Sizes
| Vial Size | Kit Price | Per Vial | Per mg | Stock |
|---|---|---|---|---|
| 5 mg← selected | $75 | $7.50 | $1.50/mg | ○ Out of Stock |
| 10 mg | $100 | $10.00 | $1.00/mg | ○ Out of Stock |
| 20 mg | $190 | $19.00 | $0.95/mg | ○ Out of Stock |
| 30 mg | $210 | $21.00 | $0.70/mg | ○ Out of Stock |
| 50 mg | $350 | $35.00 | $0.70/mg | ○ Out of Stock |
| 60 mg | $400 | $40.00 | $0.67/mg | ○ Out of Stock |
| 100 mg | $740 | $74.00 | $0.74/mg | ○ Out of Stock |
Last changed: 4h ago
Summary
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data reported average weight loss exceeding 17% over 24 weeks, making it one of the most potent compounds studied in this class. The glucagon component may further enhance lipolysis and energy expenditure beyond dual agonists.
Think of it as tirzepatide's more aggressive sibling. It hits three 'stop eating and burn fat' hormones at once instead of two. Early trial data showed some of the largest weight losses ever recorded in a drug study — up to 24% body weight. Still investigational; not yet approved anywhere.
Mechanism of Action↓
Simultaneous activation of GLP-1R (appetite suppression, incretin effect), GIPR (adipose lipolysis signaling, incretin amplification), and GCGR (glucagon receptor; increased hepatic glucose output antagonized by GLP-1, net effect on energy expenditure and fat oxidation). Triple agonism may reduce adipose tissue mass more effectively than dual approaches.
Half-life: ~6 days (estimated from phase 2 PK data)
Research Dosing Ranges↓
1 mg – 12 mg
Once weekly subcutaneous injection
Phase 2 doses ranged 1–12 mg with step-up titration. 8 mg and 12 mg arms showed the greatest weight reduction.
Reconstitution Guidance↓
BAC water: 1 mL
Resulting concentration: 100 mg/mL (for 100 mg vial)
100 mg vials are high-concentration. Add 1 mL BAC water for 100 mg/mL. Dose volumes will be very small (e.g., 80 µL = 8 mg). Use a precision 0.3 mL insulin syringe.
Storage & Stability↓
Lyophilized: 2–8°C preferred. Reconstituted: refrigerate, use within 28 days.
Known Side Effects / Contraindications↓
Similar to tirzepatide: nausea, vomiting, diarrhea, decreased appetite. Glucagon component may cause increased heart rate. Phase 2 safety profile comparable to GLP-1 class.
Price History
Showing history for the 5 mg vial.
Change History
Reconstitution Calculator
Concentration
1.67 mg/mL
Volume per dose
2400.0 µL
U-100 units
240.0 units
Doses per vial
1.3
Cost per dose
$6.00(based on kit price)
Show math
Concentration: 5 mg ÷ 3 mL = 1.67 mg/mL (1667 µg/mL)
Dose needed: 4000 µg = 4.0000 mg
Volume per dose: 4.0000 mg ÷ 1.67 mg/mL = 2.4000 mL
On U-100 syringe: 2400.0 µL = 240.0 units
Total doses in vial: 5 mg ÷ 4.0000 mg = 1.3 doses
⚠ Research Reference Only
All dosage information, mechanisms, and research data on this site are provided for educational and research reference purposes only. This is not medical advice. These compounds are not approved for human use or consumption. Always consult a licensed medical professional and comply with your local regulations.